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SRPIN340Patients of congenital diseases such as Down syndrome (DS) and Duchenne muscular dystrophy (DMD) have
abnormalities in their chromosomes and/or genes. Therefore, it has been considered that drug treatments can
serve to do little for these patients more than to patch over each symptom temporarily when it arises. Al-
though we cannot normalize their chromosomes and genes with chemical drugs, we may be able to manip-
ulate the amounts and patterns of mRNAs transcribed from patients' DNAs with small chemicals. Based on
this simple idea, we have looked for chemical compounds which can be applicable for congenital diseases
and found that protein kinase inhibitors such as INDY, TG003, and SRPIN340 are promising as clinical
drugs for DS, DMD, and DDS, respectively.
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Congenital genetic disorders are caused by hereditary or sponta-
neous genetic alterations. Genetic changes may involve a single to
several base mutations of a single gene, gene chimerization due to
chromosomal dislocations, or ampliﬁcation or deletion of multiple
genes. Genetic changes may extend to larger genetic lesions of a chro-
mosome and sometimes even its entire portion is deleted or ampli-
ﬁed. The genetic changes may result in gain or reduction in theuscular dystrophy; Clk, Cdc-2
chenne muscular dystrophy;
n regulated kinase 1A; DS,
rillary tangles; PTC, premature
y and Developmental Biology,
noe, Sakyo-ku, Kyoto 606-8501,
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NC-ND license.activity, altered function, or total loss of the genomic products, lead-
ing to the disease phenotypes. Treatments of congenital genetic disor-
ders often pose difﬁcult clinical challenges, because there are
currently no established methods to restore the genetic changes
that cause the disease. Gene therapy, the therapeutic strategy that
transfers genetic materials such as DNA and RNA to affected organs,
has been intensely studied (Kay, 2011). To date, however, no gene
therapy protocols have been approved by the Food and Drug Admin-
istration or European Medicines Agency, partly because of technical
problems involving their delivery, immunogenicity, and adverse ef-
fects (Kay, 2011).
The advancement of the knowledge of the molecular mechanisms
that link particular genetic changes with the clinical disease symptoms
began to attract the attentions of researchers on previously overlooked
molecular targets. In this review, we discuss the emerging strategies to
treat congenital genetic diseases with small chemical compounds and
summarize our recent ﬁndings on potential drug seeds for Down syn-
drome (DS), Duchenne muscular dystrophy (DMD), and Denys Drash
Syndrome (DDS).
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Some congenital genetic defects cause diseases because of the re-
duced activities of the affected gene products due to deletions or loss-
of-function mutations. In other cases, ampliﬁed copies of genomic
lesions that contain pathogenic genes, or mutations that generate ab-
normal active forms of enzymes may cause the diseases. Chemical
compounds may then counter the pathogenic process if it agonizes
the reduced activities, or antagonizes the aberrant activities of the
gene products. This approach is a rather conventional strategy
where drug compounds target the pathogenic proteins. In case of dis-
eases caused by gene ampliﬁcation, chemical compounds may pro-
vide particularly ideal therapeutics; when a gene ampliﬁcation
makes an excessive activity of a pathogenic protein, carefully dose-
controlled administration of its inhibitor may restore the enzymatic
activity to normal levels. Since pharmacokinetic/pharmacodynamics
analysis is best studied in conventional drug treatment, chemical
compound drug would be more suitable compared to other therapeu-
tic approaches such as gene therapy (Rajman, 2008). We recently
invented an inhibitor of a DS-related kinase as a potential drug lead
compound of DS as discussed later in this review.
1.2. “Ribonucleic acid-targeting” approach to treat congenital genetic
defects
The emerging concept of “RNA-targeted” chemical therapy repre-
sents the idea to target the abnormal mRNA, not the protein, to ame-
liorate the disease symptoms. Currently investigated RNA-targeting
drugs include conventional small chemical compounds and gene
therapies using target sequence-speciﬁc oligonucleotides (Hagiwara,
2005; Muntoni & Wood, 2011). In this review we will focus on the
former category of the RNA-targeting drugs.
When a gene functions as a mature protein, it must be ﬁrstly tran-
scribed and processed to a mature mRNA and then translated as a
protein. The production of mature mRNAs involves multiple coordi-
nated posttranscriptional modiﬁcations, including 5′ capping, pre-
mRNA splicing, and polyadenylation (Licatalosi & Darnell, 2010).
Other post transcriptional modiﬁcations of mRNAs include C–U and
A–I RNA editing catalyzed by APOBEC1 or ADAR proteins, respectively
(Mattick & Mehler, 2008). The mature form of mRNA then undergoes
a series of dynamic regulations that deﬁne the life span, translation
efﬁciency, and the mode of their destruction, including surveillance
of premature stop codons via nonsense mediated-decay, and silenc-
ing by micro RNAs (Dreyfuss et al., 2002). Although each of these pro-
cesses may represent potential targets for altering affected gene
activities, this review will mainly discuss about the discovery of
chemical compounds that manipulate the pre-mRNA splicing process.
In some congenital genetic diseases, regulatory sequences of splicing
are mutated, leading to production of aberrant forms of alternatively
spliced mRNAs that impair the normal functions of affected organs.
The chemical drugs may then restore the splicing patterns by
targeting the enzymes that regulate the splicing machineries, such
as SR protein kinases (SRPKs) and Cdc-2 like kinases (Clks) that phos-
phorylate and regulate the activities of splicing regulatory proteins
(Muraki et al., 2004; Hagiwara, 2005; Fukuhara et al., 2006; Yomoda
et al., 2008).
2. Chemical treatment of Down syndrome
2.1. Down syndrome is a “gene dosage” disorder
DS is the most frequent chromosomal disorder that arises once in
every 733 births in the United States (Sherman et al., 2007). DS is a
congenital genetic disorder, caused by a complete or partial trisomy
of human chromosome 21, and the triplicated genes exert excessive
activities due to the gene dosage effects leading to formation of thedisease (Antonarakis & Epstein, 2006; Wiseman et al., 2009). Patients
of DS exhibit mental retardation associated with abnormal brain de-
velopment, marked by reduced number and size of neurons, reduced
dendritic tree and smaller brain size (Coyle et al., 1986). Another
hallmark of DS is its associations with early-onset Alzheimer disease
(AD). Studies of the brains of AD revealed that DS is strongly
associated with early-onset AD. Strikingly, virtually all individuals
with DS develop the typical AD histopathology of neuroﬁbrillary tan-
gles (NFT) and amyloid plaques when they are above the age of 30,
and between 50 and 70% of DS individuals develop dementia by the
age of 60 (Wisniewski et al., 1985; Antonarakis & Epstein, 2006;
Wiseman et al., 2009). Other systemic manifestations including men-
tal retardation, cardiovascular anomalies, craniofacial dysmorphol-
ogy, malignant neoplasms such as acute myoblastic leukemia, and
recurrent infections, are also seen in DS patients (Antonarakis &
Epstein, 2006; Wiseman et al., 2009).
2.2. Dual-speciﬁcity tyrosine-(Y)-phosphorylation
regulated kinase 1A is a potential drug target of Down syndrome
DYRK1A (dual-speciﬁcity tyrosine-(Y)-phosphorylation regulated
kinase 1A) is a serine/threonine kinase that is essential in the mainte-
nance of normal development and function of the brain (Becker et al.,
1998; Wiseman et al., 2009). The physiological importance of DYRK1A
has recently been highlighted by its proposed relation with the path-
ogenesis of DS. This review brieﬂy summarizes the proposed relation-
ship of DYRK1A and DS, but the physiological function of DYRK1A and
its pathogenic role in DS is extensively reviewed elsewhere (Becker &
Sippl, 2011; Tejedor & Hammerle, 2011; Wegiel et al., 2011).
Initially, DYRK1A attracted the interest of researchers when it was
found within the ‘Down Syndrome Critical Region (DSCR)’ of human
chromosome 21, the genomic region that was considered to explain
the most of the DS symptoms at that time (Guimera et al., 1996;
Shindoh et al., 1996; Song et al., 1996). Although now it is revealed
that the complex gene interactions that include genes outside the
DSCR contribute to various DS phenotypes, DCSR genes are still con-
sidered to contribute to the neuropsychiatric manifestations (Olson
et al., 2007; Korbel et al., 2009). Importantly, the extra copy of
DYRK1A gene in DS indeed results in 1.5-fold increase of DYRK1A
product both at mRNA and protein levels in their brain (Guimera et
al., 1999; Dowjat et al., 2007; Liu et al., 2008; Wegiel et al., 2008;
Vilardell et al., 2011). It is proposed that this subtle increase of the en-
zymatic activity takes a broad consequence on the aberrant develop-
ment of the brain.
Another observation that links DYRK1A to DS pathogenesis is its
essential role on neurogenesis and neural differentiation. The molec-
ular targets of DYRK1A make an ever increasing list that currently in-
cludes more than 20 substrates and a dozen of interactive proteins
(Tejedor & Hammerle, 2011). Through such phosphorylation events
and protein interactions, DYRK1A functions in a remarkably broad as-
pect of cellular processes such as cell cycle regulation, cellular signal-
ing, chromatin modulation and gene expression, regulation of
alternative splicing, and membrane trafﬁcking (Tejedor &
Hammerle, 2011). DYRK1A thus regulates the neurogenesis, neural
differentiation, dendritogenesis, synapse function and cell death
(Wegiel et al., 2011). To exert the diversiﬁed roles throughout the
life cycle of neurons, DYRK1A itself shows a regulated spatiotemporal
expression and cellular localization that changes according to differ-
ent stages of neural development by yet unknown mechanisms
(Hammerle et al., 2003; Hammerle et al., 2008; Kida et al., 2011).
Considering its signiﬁcant breadth of cellular functions, DYRK1A may
function as a coordinator/balancer in developing neurons, and its im-
balance may induce profound change in brain functions.
Lastly and most importantly, several studies using different lines
of transgenic mice revealed that overexpression of Dyrk1A alone is
sufﬁcient to induce brain morphology alterations as well as
Fig. 1. Structure of INDY, TG003, and SRPIN340.
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tions (Smith et al., 1997; Altafaj et al., 2001; Branchi et al., 2004;
Martinez de Lagran et al., 2004; Ahn et al., 2006; Altafaj et al., 2008;
Laguna et al., 2008; Ortiz-Abalia et al., 2008; Sebrie et al., 2008).
There are several genetically modiﬁed mouse lines that overexpress
Dyrk1A; that are due to ampliﬁcation of murine chromosome 16
(Ts65Dn, Ts1Cje, TsRhr, etc.) (Guimera et al., 1999; Dowjat et al.,
2007; Liu et al., 2008; Roubertoux & Carlier, 2010; Yu et al., 2010),
human chromosome 21 (Tc1)(O'Doherty et al., 2005), introduction
of yeast artiﬁcial chromosome (152 F7) (Smith et al., 1997; Branchi
et al., 2004), bacterial artiﬁcial chromosome (DYRK1A BAC mouse)
(Ahn et al., 2006), and single gene overexpression (TgDyrk1A)
(Altafaj et al., 2001; Martinez de Lagran et al., 2004; Altafaj et al.,
2008; Ortiz-Abalia et al., 2008). They commonly exhibit cognitive de-
fects, such as learning and memory impairment, although the alter-
ation of brain morphologies, and size are not always consistent
between these animals, possibly reﬂecting the complex genetic
interactions.
2.3. Misregulated alternative splicing in Down syndrome
Although DS is a typical “gene dosage” disease, DS also has an as-
pect of disease mediated by misregulated alternative splicing of mul-
tiple mRNAs. DYRK1A phosphorylates the splicing factors such as
SRSF1/ASF, SRSF2/SC35, SRFS7/9G8 and SF3B1/SAP155 (de Graaf et
al., 2006; Shi et al., 2008; Ding et al., in press; Qian et al., 2011).
SRSF1/ASF, SRSF2/SC35 and SRFS7/9G8 belong to the SR protein fam-
ily of splicing factors that contain Ser/Arg rich domains. SR proteins
bind to speciﬁc elements of pre-mRNA and enhance or suppress the
inclusion of alternative exons. Their activities are regulated by phos-
phorylation of the RS domains and thus changes in activities of their
upstream kinases may exert global effect on alternative splicing pat-
terns (Long & Caceres, 2009; Shepard & Hertel, 2009). Toiber et al.
reported that in fetal DS brains, phosphorylation levels of SR proteins
were elevated, and in addition, gene expression levels of multiple
splicing related proteins were altered. They examined the mRNAs of
TRKB and AChE in fetal DS brains and found changes in alternative
splicing patterns in a way that may contribute to the DS phenotype.
Stable overexpression of Dyrk1A in mouse brain mimicked these ﬁnd-
ings if not completely (Toiber et al., 2010).
2.4. Role of dual-speciﬁcity tyrosine-(Y)-phosphorylation
regulated kinase 1A in Down syndrome associated Alzheimer disease
Excessive activities of DYRK1Amay accelerate AD pathogenesis be-
cause it results in the formation of neurotoxic NFT in AD brains
through twomechanisms; by triggering the multiple phosphorylation
of the tau protein, and by inducing aberrant alternative splicing of tau.
In vitro experiments showed that DYRK1A phosphorylates the tau
protein at Thr212, then the phosphorylated tau became prone to
phosphorylation by GSK3β and other kinases at multiple sites, lead-
ing to its pathogenic aggregation and formation of NFT (Woods et
al., 2001; Ryoo et al., 2007; Liu et al., 2008). Studies of the AD patient
brains revealed the increased expression of DYRK1A in both the
brains and the speciﬁc neurons affected by tau aggregation (Ferrer
et al., 2005; Kimura et al., 2007; Wegiel et al., 2008). NFT formation
is also enhanced by the imbalanced alternative splicing of its pre-
mRNA. Exon 10 inclusion/exclusion of tau is regulated by SR proteins
SRSF1/ASF and SRSF2/SC35 that are substrates of DYRK1A (Shi et al.,
2008; Qian et al., 2011). SRSF1/ASF and SRSF2/SC35 bind to exonic
splicing enhancers at exon 10 and promote its inclusion in mRNA
thus generating the 4R-tau form. Phosphorylation of these SR pro-
teins by DYRK1A releases these splicing factors from the splicing en-
hancers and results in formation of 3R-tau that lacks exon 10 (Shi et
al., 2008; Qian et al., 2011). In a normal state, nearly equal amount
of 3R-tau and 4R-tau, forms of tau, is expressed in adult brain. If thisbalance is lost and turns to 3R-tau predominance, tauopathy is in-
duced (Liu & Gong, 2008). Other reports show the direct and indirect
association of excess DYRK1A activity and enhanced toxicity of amy-
loid precursor protein that also plays an essential role in AD patho-
genesis (Ryoo et al., 2008).
2.5. INDY, a novel inhibitor
of dual-speciﬁcity tyrosine-(Y)-phosphorylation regulated kinase 1A
In order to invent the potential DS and AD drugs, we searched for
speciﬁc inhibitors of DYRK1A, and found that benzothiazole derivatives
have a potent inhibitory effect on the kinase activity. Among them,
(1Z)-1-(3-ethyl-5-hydroxy-2(3H)-benzothiazoylidene)-2-propanone,
which we referred to as INDY (inhibitor of Dyrk) (Fig. 1), was the most
potent compound with an IC50 of 0.24 μM (Ogawa et al., 2010). INDY
also inhibited DYRK1B, the closest DYRK kinase family member to
DYRK1A, with an IC50 of 0.23 μM. Otherwise, INDY had high kinase se-
lectivity; in an in vitro assay screening using a panel of 66 protein ki-
nases, INDY (10 μM) showed >90% inhibition on DYRK2, DYRK3 and
four other kinases, namely CLK1, CLK4, CSNK1D and PIM1. The X-ray
crystallography of the DYRK1A/INDY complex revealed the binding of
INDY in the ATP pocket of the enzyme (Ogawa et al., 2010).
Harmine, a plant alkaloid, is one of the most potent DYRK1A inhibi-
tor reported to date (Bain et al., 2007; Gockler et al., 2009). Inhibition of
DYRK1A by INDY was comparable to that by harmine, which showed a
higher IC50 (0.35 μM) in our assay compared to the past reports, pre-
sumably due to the different experimental conditions. Interestingly,
harmine also inhibited Clks at a level comparable to the inhibition by
INDY, implying a similar structural mechanism of inhibitory action. Un-
fortunately, utility of harmine in the ﬁeld of brain research is limited by
the fact that it also inhibits monoamine oxidase (MAO) A at a consider-
ably lower dose (IC50=5 nM) than required for inhibiting DYRK and
Clk family kinases (Kim et al., 1997). INDY, however, was substantially
free of MAOA inhibitory activity. Their similar kinase inhibitory poten-
tial and the contrasting difference in MAOA inhibitory potential were
explained by comparing the X-ray crystallographies. INDY and harmine
employed markedly similar manner to bind the DYRK1A ATP pocket; a
result that is consistent with the observed kinase selectivity of the two
compounds. In case ofMAOA, INDY could reproducemany hydrophobic
interactions between harmine andMAOA, according to the hypothetical
INDY/MAOA complex structure deduced from reported harmine/MAOA
model. Itwas suggested, however, that INDYmay interferewith Asn181
or Phe208 ofMAOA, aswell as disturb a network of water-mediated hy-
drogen bonds of MAOA, thus preventing the complex formation
(Ogawa et al., 2010).
In cultured cells, INDY effectively reversed the aberrant tau phos-
phorylation and rescued the skewed cellular signaling events induced
by DYRK1A overexpression. To further validate the utility of the
DYRK1A inhibitor, we developed a novel in vivo assay. For this purpose
we utilized Xenopus laevis embryo as an ideal platform to observe the
general effects of Dyrk1A overexpression, because it allows an in vivo
assay at a level of whole vertebrate development while also allowing
a relatively high throughput.When Xenopus Dyrk1AmRNAwas injected
into two animal dorsal blastomeres of 8-cell embryos, deformity was
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by dorsal deformation in some cases. Importantly, proINDY, a prodrug
of INDY, effectively recovered Xenopus embryos from head malforma-
tion induced by Xenopus Dyrk1A overexpression, resulting in normally
developed embryos (Ogawa et al., 2010). These experiments demon-
strate the utility of proINDY in vivo, indicating the possibility that
INDY and proINDY have therapeutic utility on neuropsychiatric symp-
toms of DS and early onset AD associated with DS. Further studies
using DS and AD model mice are warranted to prove their clinical ben-
eﬁts of these DYRK1A inhibitors.
3. Chemical treatment of muscular dystrophies
3.1. TG003, as a mutated-exon skipping enhancer
DMD is themost common inheritedmuscle disease and is caused by
amutation in the dystrophin gene, the largest in the human genome, on
the X chromosome 1 (Koenig et al., 1988). Because of progressive mus-
cle wasting, DMD patients usually succumb to cardiac or respiratory
failure in their twenties. Becker muscular dystrophy (BMD) is a milder
allelic variant of DMD, usually affecting adult males. Nonsense muta-
tions or deletions causing frame shifts in the dystrophin mRNA, both
of which create premature termination codons (PTCs), usually result
in a severe DMD phenotype, because of a lack of the dystrophin protein
(Monaco et al., 1988). Recently, we met a dystrophinopathy patient
who has a previously unreported point mutation in exon 31 of the dys-
trophin gene that was not seen in more than 400 other dystrophinopa-
thy patients we studied. Although themutation generates a stop codon,
a small amount of internally deleted, but functional, dystrophin protein
was produced in the patient cells. An analysis of themRNA revealed that
the mutation promotes exon skipping and restores the open reading
frame of dystrophin (Nishida et al., 2011). We found that the
c.4303G>T mutation in this patient disrupted an exonic splicing en-
hancer that promotes exon 31 inclusion. Interestingly, the mutation si-
multaneously produced an exonic splicing silencer that binds to hnRNP
A1 and promotes skipping of the same exon. Skipping of 111-bp-long
exon 31 results in an in-ﬂame internal deletion that leads to the produc-
tion of an internally deleted but functional dystrophin. We hypothe-
sized that a customized RNA-targeted therapy speciﬁc for this patient
would become possible by promoting the skipping of the exon 31
(Fig. 2). Therefore we searched for small chemicals that enhance exon
skipping, and found that TG003, which is a compound we developed
as a speciﬁc inhibitor Clk1 and Clk4, promoted the skipping of exonex 30
ex 30 ex 32ex 31
ORF
No protein
Sto
Stop codon
Fig. 2. Strategy for treatment of Duchenne muscular dystrophy. The DMD patient with c.4303
skipping of the 111 bp-long exon 31 produces an internally deleted, functional dystrophin
protein.31 in the endogenous dystrophin gene in a dose-dependent manner
and increased production of the dystrophin protein in the patient's
cells (Fig. 1) (Muraki et al., 2004; Nishida et al., 2011). Since Clk1 and
Clk4 kinase activity regulates alternative splicing events by phosphory-
lating some SR proteins, TG003 may produce an unphosphorylated
form of a SR protein that functions as an inhibitor of exon 31 inclusion
and enhances exon skipping corporately with hnRNPA1. TG003 did
not affect splicing of wild type exon 31 or other normal exons of the
dystrophin gene.
Though more preclinical studies with animal models are needed,
TG003 is the ﬁrst chemical compound veriﬁed to improve dystrophin
production in in vitro patient-derived myotubes.
3.2. Stop codon read through drugs
A part of DMDs are caused by premature stop codons in the dystro-
phin gene that arise from the gene mutation (Muntoni et al., 2003).
Some aminoglycoside antibiotic such as gentamicin allows the ribo-
some machinery to skip or “read through” the stop codons (Wagner
et al., 2001) (Fig. 3). Treatment of the mdx mouse, a model mouse of
nonsense mutation of DMD, with gentamicin increased the expression
of dystrophin by up to 20%, and improved the muscle manifestations
(Wagner et al., 2001). Since prolonged systemic administration of gen-
tamicin has the adverse effect of nephrotoxicity and ototoxicity, alter-
native therapeutic chemical compounds have been developed.
PTC124, a small chemical developed by PTC Therapeutics, is an orally
administrated drug that targets the 60S ribosomal subunit and induces
the selective read through of the nonsense mutations. Experiments
withmdxmice demonstrated somewhat better ability of PTC124 in re-
covery of their muscle phenotypes compared to gentamicin (Welch et
al., 2007). Phase I studies for PTC124 showed that this drug is well tol-
erated, and data from a Phase IIb study suggested that PTC124 has clin-
ical beneﬁt in nonsense mutation-DMD patient when it is used in
relatively low doses but not in high doses (PTC Therapeutics website,
http://www.ptcbio.com/). PTC124 is now in Phase III trials in cystic ﬁ-
brosis patients who have disease-causing premature stop codons in
CFTR gene (ClinicalTrials.gov identiﬁer: NCT01140451).
3.3. RNA binding compounds
The other strategy to develop “RNA-targeting” drugs is to ﬁnd com-
pounds that bind to RNA itself. Myotonic dystrophy (MD) is an inher-
ited neuromuscular degenerative disease, characterized by muscularex 32ex 31
ex 30 ex 32
ORF
Dystrophin protein
p codon
+TG003
G>T mutation has a premature termination codon in exon 31 of dystrophin gene. Exon
product. TG003 enhances the exon 31 skipping leading to an increase of the functional
Ribosome
PTC Stop codon
mRNA
Truncated protein
Nonsense mediated decay
+PTC124
Skipped PTC
Full length protein
Fig. 3. Premature stop codon read through strategy. The small chemical compound PTC124 suppresses premature termination codons and allows increased production of full length
proteins.
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paired glucose tolerance, cataracts, and cardiac abnormalities (La
Spada et al., 1994). Two types of MD, namely MD1 and MD2, have
been well characterized (Lee & Cooper, 2009). MD1, that is estimated
to affect ~1 in 8500 individuals, is caused by the mutation of the
DMPK gene. In MD1 patients, 3′ UTR of the DMPK gene contains aber-
rantly expanded trinucleotide repeats of CTG. In case of MD2, tetranu-
cleotide repeats of CCTG are expanded in the ﬁrst intron of the CNBP
gene (Lee & Cooper, 2009). When transcribed into pre-mRNAs, these
nucleotide repeats inﬂict the pathogenic potentials through the RNA
gain-of-function mechanism (Fig. 4). In case of MD1, the expanded
CUG repeat captures the splicing factor muscleblind-like protein 1
(MBNL1) and results in relative loss of function of the protein, while an-
other splicing factor, CUG triplet repeat RNA binding protein 1
(CUGBP1), is upregulated due to altered cellular signaling eventsa
b
Fig. 4. Strategy for chemical treatment of myotonic dystrophy. (a) The expanded CUG repea
MBNL1. CUG expansion also leads to relative gain of function of another splicing factor CUG
(b) Pentamidine restores normal alternative splicing by neutralizing the effect of CUG repeinvolving protein kinase C (Philips et al., 1998; Miller et al., 2000;
Kuyumcu-Martinez et al., 2007; Lee & Cooper, 2009; Wang et al.,
2009). Since MBNL1 and CUGBP1 are key splicing factors that regulate
the global alternative splicing patterns, subsequent dysregulation of al-
ternative splicing results in systemic dysfunctions including themuscu-
lar dystrophy (Mankodi et al., 2000). In a search for small chemical
inhibitors that counter the RNA gain-of-function effect in DM1, Warf
MB et al. found that pentamidine, an antibiotic used in Pneumocystis
pneumonia, binds to the CUG repeats and inhibits the binding of
MBNL1 in vitro (Fig. 4). Using a mouse model that expresses expanded
CUG repeats, they demonstrated that pentamidine rescues missplicing
events in the muscle at least partially, although full rescue was not
achieved due to the toxicity of the drug that appeared in high dose
treatments (Warf et al., 2009). Development of improved compounds
with higher speciﬁcity to CUG repeats is awaited.ts in the DMPKmRNA sequestrate and result in the loss of function of the splicing factor
BP1. Imbalance of MBNL1 and CUGBP1 results in disordered alternative splicing events.
at expansion via competitive binding.
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4.1. SRPIN340, as another alternative splicing-modifying chemical drug
SRPKs represent another kinase family that phosphorylates SR pro-
teins and regulates alternative splicing patterns (Gui et al., 1994;
Kuroyanagi et al., 1998). In search of novel chemical splicing modifying
drugs, we performed an extensive screening of 100,000 chemical com-
pounds, and found a synthetic compound as speciﬁc inhibitors of SR
protein kinases (SRPKs) (Fukuhara et al., 2006). The compound,
whichwe named SRPIN340, had potential clinical utilities in treatments
of viral infection and anti-angiogenesis therapies against retinal neovas-
culization and certain tumors (Fukuhara et al., 2006; Karakama et al.,
2010; Nowak et al., 2010; Amin et al., 2011) (Fig. 1).
Vascular Endothelial Growth Factor (VEGF) is a key regulatory com-
ponent in physiological and pathological angiogenesis. Two types VEGF
isoforms, the pro-angiogenic isoforms and the anti-angiogenic isoforms
are generated by splice site choice in the exon 8. Proximal splice site se-
lection in exon 8 generates pro-angiogenic isoforms such as VEGF165,
and distal splice site selection results in anti-angiogenic isoforms such
as VEGF165b (Qiu et al., 2009). Epithelial cells treated with IGF-1 in-
creased proximal splice site selection and produced more angiogenic
isoforms. On the contrary, SRPK1/2 inhibition promoted distal splice
site selection and produced more anti-angiogenic isoforms (Nowak et
al., 2010) (Fig. 5). Injection of SRPIN340 reduced angiogenesis in a
model of retinal neovascularization (Nowak et al., 2010). DDS patients
who have a genetic mutation in the Wilm's tumor suppressor gene
WT1 have increased risk of Wilm's tumor, a highly vascularized tumor
with high VEGF levels. A recent study demonstrated that SRPIN340
functions as anti-angiogenic drugs for these tumors by switching the
splicing pattern of VEGF toward the production of anti-angiogenic
VEGF165b and other anti-angiogenic isoforms (Amin et al., 2011).
5. Conclusion
For many congenital genetic diseases, no treatments are available
besides common palliative therapies. We sought for novel cure for
two such congenital diseases, DS and DMD, and identiﬁed INDY and
TG003 as possible chemical therapeutic agents. In addition, SRPIN340
may be applicable for anti-angiogenic therapy such as those against
Wilm's tumors of DDS patients.
Current sophisticated sequencing techniques allow us to sequence
the human genomes and transcriptomes in a reasonably affordable
cost and time (Ku et al., 2011). It gives us the hope that genetic defects
of a given patient may be pinpointed to a single base in the near future
and that we thenmay be able to understand the precisemolecular basis
of the disease on the level of the RNA life cycle. In addition, consideringFig. 5. Strategy for chemical treatment of DDS. VEGF gene produces pro- and anti-
angiogenic alternative splicing isoforms by the selective usage of the splicing site in the
last exon. Activation of SRPK1/2 results in an increase in the pro-angiogenic isoforms
(e.g. VEGF165). Inhibition of SRPK1/2 by SRPIN340 results in increased production of
anti-angiogenic isoforms (e.g. VEGF165b).that many well-designed, large chemical libraries being now increas-
ingly accessible, more chemical tools are expected to turn out in the
near future that allows us ﬁne manipulations of RNA processing
(Thomas et al., 2009; Roy et al., 2010). Combined with the advancing
knowledge on the mechanisms how the splicing codes are deciphered
and how to manipulate them, RNA targeted therapies would be
designed according to the gene alteration and the following mRNA de-
fects unique to individual patients as the researches will advance in this
exciting ﬁeld.
While it is not yet possible to restore the disease-causing genetic ab-
errations in the level of DNA, new drugs may be discovered that miti-
gate the disease symptoms by chemically manipulating the amounts
and patterns of disease-causing mRNAs. For future development of
small chemical compound drugs for many genetic diseases, more re-
search must be aimed at the molecular mechanisms that can inﬂuence
the mRNA processing and functions, as well as knowledge of key mole-
cules that are central to the pathogenesis of each disease.
Acknowledgment
This work was supported by Core Research for Evolutional Science
and Technology (CREST) Program and other research grants from the
Japan Science and Technology Agency (JST), Health and Labour Sci-
ences Research Grants, Grants-in-aid from the Ministry of Education,
Culture, Sports, Science, and Technology (MEXT), a grants from
Takeda Science Foundation and Uehara Memorial Foundation.
References
Ahn, K. J., Jeong, H. K., Choi, H. S., Ryoo, S. R., Kim, Y. J., Goo, J. S., Choi, S. Y., Han, J. S., Ha,
I., & Song, W. J. (2006). DYRK1A BAC transgenic mice show altered synaptic plastic-
ity with learning and memory defects. Neurobiol Dis 22, 463–472.
Altafaj, X., Dierssen, M., Baamonde, C., Marti, E., Visa, J., Guimera, J., Oset, M., Gonzalez,
J. R., Florez, J., Fillat, C., & Estivill, X. (2001). Neurodevelopmental delay, motor ab-
normalities and cognitive deﬁcits in transgenic mice overexpressing Dyrk1A
(minibrain), a murine model of Down's syndrome. Hum Mol Genet 10, 1915–1923.
Altafaj, X., Ortiz-Abalia, J., Fernandez, M., Potier, M. C., Laffaire, J., Andreu, N., Dierssen,
M., Gonzalez-Garcia, C., Cena, V., Marti, E., & Fillat, C. (2008). Increased NR2A ex-
pression and prolonged decay of NMDA-induced calcium transient in cerebellum
of TgDyrk1A mice, a mouse model of Down syndrome. Neurobiol Dis 32, 377–384.
Amin, E. M., Oltean, S., Hua, J., Gammons, M. V., Hamdollah-Zadeh, M., Welsh, G. I.,
Cheung, M., Ni, L., Kase, S., Rennel, E. S., Symonds, K. E., Nowak, D. G., Pokora-
Royer, B., Saleem, M. A., Hagiwara, M., Schumacher, V. A., Harper, S. J., Hinton,
D. R., Bates, D. O., & Ladomery, M. R. (2011). WT1 mutants reveal SRPK1 to be a
downstream angiogenesis target by altering VEGF splicing. Cancer Cell 20, 768–780.
Antonarakis, S. E., & Epstein, C. J. (2006). The challenge of Down syndrome. Trends Mol
Med 12, 473–479.
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I., Arthur,
J. S., Alessi, D. R., & Cohen, P. (2007). The selectivity of protein kinase inhibitors: a
further update. Biochem J 408, 297–315.
Becker, W., & Sippl, W. (2011). Activation, regulation, and inhibition of DYRK1A. FEBS J
278, 246–256.
Becker, W., Weber, Y., Wetzel, K., Eirmbter, K., Tejedor, F. J., & Joost, H. G. (1998). Se-
quence characteristics, subcellular localization, and substrate speciﬁcity of DYRK-
related kinases, a novel family of dual speciﬁcity protein kinases. J Biol Chem 273,
25893–25902.
Branchi, I., Bichler, Z., Minghetti, L., Delabar, J. M., Malchiodi-Albedi, F., Gonzalez, M. C.,
Chettouh, Z., Nicolini, A., Chabert, C., Smith, D. J., Rubin, E. M., Migliore-Samour, D.,
& Alleva, E. (2004). Transgenic mouse in vivo library of human Down syndrome
critical region 1: association between DYRK1A overexpression, brain development
abnormalities, and cell cycle protein alteration. J Neuropathol Exp Neurol 63,
429–440.
Coyle, J. T., Oster-Granite, M. L., & Gearhart, J. D. (1986). The neurobiologic conse-
quences of Down syndrome. Brain Res Bull 16, 773–787.
de Graaf, K., Czajkowska, H., Rottmann, S., Packman, L. C., Lilischkis, R., Luscher, B., &
Becker, W. (2006). The protein kinase DYRK1A phosphorylates the splicing factor
SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site. BMC Biochem 7, 7.
Ding, S., Shi, J., Qian, W., Iqbal, K., Grundke-Iqbal, I., Gong, C.X., & Liu, F. in press. Regu-
lation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A. Neurobiol Aging.
Dowjat, W. K., Adayev, T., Kuchna, I., Nowicki, K., Palminiello, S., Hwang, Y. W., &
Wegiel, J. (2007). Trisomy-driven overexpression of DYRK1A kinase in the brain
of subjects with Down syndrome. Neurosci Lett 413, 77–81.
Dreyfuss, G., Kim, V. N., & Kataoka, N. (2002). Messenger-RNA-binding proteins and the
messages they carry. Nat Rev Mol Cell Biol 3, 195–205.
Ferrer, I., Barrachina, M., Puig, B., Martinez de Lagran, M., Marti, E., Avila, J., & Dierssen, M.
(2005). Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down
syndrome, Pick disease, and related transgenic models. Neurobiol Dis 20, 392–400.
304 Y. Ogawa, M. Hagiwara / Pharmacology & Therapeutics 134 (2012) 298–305Fukuhara, T., Hosoya, T., Shimizu, S., Sumi, K., Oshiro, T., Yoshinaka, Y., Suzuki, M.,
Yamamoto, N., Herzenberg, L. A., Herzenberg, L. A., & Hagiwara, M. (2006). Utiliza-
tion of host SR protein kinases and RNA-splicing machinery during viral replica-
tion. Proc Natl Acad Sci U S A 103, 11329–11333.
Gockler, N., Jofre, G., Papadopoulos, C., Soppa, U., Tejedor, F. J., & Becker, W. (2009).
Harmine speciﬁcally inhibits protein kinase DYRK1A and interferes with neurite
formation. FEBS J 276, 6324–6337.
Gui, J. F., Lane, W. S., & Fu, X. D. (1994). A serine kinase regulates intracellular localiza-
tion of splicing factors in the cell cycle. Nature 369, 678–682.
Guimera, J., Casas, C., Estivill, X., & Pritchard, M. (1999). Human minibrain homologue
(MNBH/DYRK1): characterization, alternative splicing, differential tissue expres-
sion, and overexpression in Down syndrome. Genomics 57, 407–418.
Guimera, J., Casas, C., Pucharcos, C., Solans, A., Domenech, A., Planas, A. M., Ashley, J.,
Lovett, M., Estivill, X., & Pritchard, M. A. (1996). A human homologue of Drosophila
minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome
and maps to the critical region. Hum Mol Genet 5, 1305–1310.
Hagiwara, M. (2005). Alternative splicing: a new drug target of the post-genome era.
Biochim Biophys Acta 1754, 324–331.
Hammerle, B., Carnicero, A., Elizalde, C., Ceron, J., Martinez, S., & Tejedor, F. J. (2003).
Expression patterns and subcellular localization of the Down syndrome candidate
protein MNB/DYRK1A suggest a role in late neuronal differentiation. Eur J Neurosci
17, 2277–2286.
Hammerle, B., Elizalde, C., & Tejedor, F. J. (2008). The spatio-temporal and subcellular
expression of the candidate Down syndrome gene Mnb/Dyrk1A in the developing
mouse brain suggests distinct sequential roles in neuronal development. Eur J Neurosci
27, 1061–1074.
Karakama, Y., Sakamoto, N., Itsui, Y., Nakagawa, M., Tasaka-Fujita, M., Nishimura-
Sakurai, Y., Kakinuma, S., Oooka, M., Azuma, S., Tsuchiya, K., Onogi, H., Hagiwara, M.,
&Watanabe, M. (2010). Inhibition of hepatitis C virus replication by a speciﬁc inhibitor
of serine–arginine-rich protein kinase. Antimicrob Agents Chemother 54, 3179–3186.
Kay, M. A. (2011). State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet
12, 316–328.
Kida, E., Walus, M., Jarzabek, K., Palminiello, S., Albertini, G., Rabe, A., Hwang, Y. W., &
Golabek, A. A. (2011). Form of dual-speciﬁcity tyrosine-(Y)-phosphorylation-regulated
kinase 1A nonphosphorylated at tyrosine 145 and 147 is enriched in the nuclei of
astroglial cells, adult hippocampal progenitors, and some cholinergic axon terminals.
Neuroscience 195, 112–127.
Kim, H., Sablin, S. O., & Ramsay, R. R. (1997). Inhibition of monoamine oxidase A by
beta-carboline derivatives. Arch Biochem Biophys 337, 137–142.
Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R.,
Tanaka, T., Kudo, T., Yamagata, H., Tabara, Y., Miki, T., Akatsu, H., Kosaka, K.,
Funakoshi, E., Nishitomi, K., Sakaguchi, G., Kato, A., Hattori, H., Uema, T., & Takeda,
M. (2007). TheDYRK1Agene, encoded in chromosome 21Down syndrome critical re-
gion, bridges between beta-amyloid production and tau phosphorylation in
Alzheimer disease. Hum Mol Genet 16, 15–23.
Koenig, M., Monaco, A. P., & Kunkel, L. M. (1988). The complete sequence of dystrophin
predicts a rod-shaped cytoskeletal protein. Cell 53, 219–228.
Korbel, J. O., Tirosh-Wagner, T., Urban, A. E., Chen, X. N., Kasowski, M., Dai, L., Grubert,
F., Erdman, C., Gao, M. C., Lange, K., Sobel, E. M., Barlow, G. M., Aylsworth, A. S.,
Carpenter, N. J., Clark, R. D., Cohen, M. Y., Doran, E., Falik-Zaccai, T., Lewin, S. O.,
Lott, I. T., McGillivray, B. C., Moeschler, J. B., Pettenati, M. J., Pueschel, S. M., Rao,
K. W., Shaffer, L. G., Shohat, M., Van Riper, A. J., Warburton, D., Weissman, S.,
Gerstein, M. B., Snyder, M., & Korenberg, J. R. (2009). The genetic architecture of
Down syndrome phenotypes revealed by high-resolution analysis of human seg-
mental trisomies. Proc Natl Acad Sci U S A 106, 12031–12036.
Ku, C. S., Naidoo, N., & Pawitan, Y. (2011). Revisiting Mendelian disorders through
exome sequencing. Hum Genet 129, 351–370.
Kuroyanagi, N., Onogi, H., Wakabayashi, T., & Hagiwara, M. (1998). Novel SR-protein-
speciﬁc kinase, SRPK2, disassembles nuclear speckles. Biochem Biophys Res Com-
mun 242, 357–364.
Kuyumcu-Martinez, N. M., Wang, G. S., & Cooper, T. A. (2007). Increased steady-state in
levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperpho-
sphorylation. Mol Cell 28, 68–78.
La Spada, A. R., Paulson, H. L., & Fischbeck, K. H. (1994). Trinucleotide repeat expansion
in neurological disease. Ann Neurol 36, 814–822.
Laguna, A., Aranda, S., Barallobre, M. J., Barhoum, R., Fernandez, E., Fotaki, V., Delabar, J. M.,
de la Luna, S., de la Villa, P., & Arbones, M. L. (2008). The protein kinase DYRK1A regu-
lates caspase-9-mediated apoptosis during retina development. Dev Cell 15, 841–853.
Lee, J. E., & Cooper, T. A. (2009). Pathogenic mechanisms of myotonic dystrophy. Bio-
chem Soc Trans 37, 1281–1286.
Licatalosi, D. D., & Darnell, R. B. (2010). RNA processing and its regulation: global in-
sights into biological networks. Nat Rev Genet 11, 75–87.
Liu, F., & Gong, C. X. (2008). Tau exon 10 alternative splicing and tauopathies.Mol Neu-
rodegener 3, 8.
Liu, F., Liang, Z., Wegiel, J., Hwang, Y. W., Iqbal, K., Grundke-Iqbal, I., Ramakrishna, N., &
Gong, C. X. (2008). Overexpression of Dyrk1A contributes to neuroﬁbrillary degen-
eration in Down syndrome. FASEB J 22, 3224–3233.
Long, J. C., & Caceres, J. F. (2009). The SR protein family of splicing factors: master reg-
ulators of gene expression. Biochem J 417, 15–27.
Mankodi, A., Logigian, E., Callahan, L., McClain, C., White, R., Henderson, D., Krym, M., &
Thornton, C. A. (2000). Myotonic dystrophy in transgenic mice expressing an ex-
panded CUG repeat. Science 289, 1769–1772.
Martinez de Lagran, M., Altafaj, X., Gallego, X., Marti, E., Estivill, X., Sahun, I., Fillat, C., &
Dierssen, M. (2004). Motor phenotypic alterations in TgDyrk1a transgenic mice
implicate DYRK1A in Down syndrome motor dysfunction. Neurobiol Dis 15,
132–142.Mattick, J. S., & Mehler, M. F. (2008). RNA editing, DNA recoding and the evolution of
human cognition. Trends Neurosci 31, 227–233.
Miller, J. W., Urbinati, C. R., Teng-umnuay, P., Stenberg, M. G., Byrne, B. J., Thornton,
C. A., & Swanson, M. S. (2000). Recruitment of human muscleblind proteins to
(CUG)(n) expansions associated with myotonic dystrophy. EMBO J 19, 4439–4448.
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988). An
explanation for the phenotypic differences between patients bearing partial dele-
tions of the DMD locus. Genomics 2, 90–95.
Muntoni, F., Torelli, S., & Ferlini, A. (2003). Dystrophin and mutations: one gene, sever-
al proteins, multiple phenotypes. Lancet Neurol 2, 731–740.
Muntoni, F., & Wood, M. J. (2011). Targeting RNA to treat neuromuscular disease. Nat
Rev Drug Discov 10, 621–637.
Muraki, M., Ohkawara, B., Hosoya, T., Onogi, H., Koizumi, J., Koizumi, T., Sumi, K.,
Yomoda, J., Murray, M. V., Kimura, H., Furuichi, K., Shibuya, H., Krainer, A. R.,
Suzuki, M., & Hagiwara, M. (2004). Manipulation of alternative splicing by a
newly developed inhibitor of Clks. J Biol Chem 279, 24246–24254.
Nishida, A., Kataoka, N., Takeshima, Y., Yagi, M., Awano, H., Ota, M., Itoh, K., Hagiwara,
M., & Matsuo, M. (2011). Chemical treatment enhances skipping of a mutated exon
in the dystrophin gene. Nat Commun 2, 308.
Nowak, D. G., Amin, E. M., Rennel, E. S., Hoareau-Aveilla, C., Gammons, M., Damodoran,
G., Hagiwara, M., Harper, S. J., Woolard, J., Ladomery, M. R., & Bates, D. O. (2010).
Regulation of vascular endothelial growth factor (VEGF) splicing from pro-
angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogen-
esis. J Biol Chem 285, 5532–5540.
O'Doherty, A., Ruf, S., Mulligan, C., Hildreth, V., Errington, M. L., Cooke, S., Sesay, A.,
Modino, S., Vanes, L., Hernandez, D., Linehan, J. M., Sharpe, P. T., Brandner, S.,
Bliss, T. V., Henderson, D. J., Nizetic, D., Tybulewicz, V. L., & Fisher, E. M. (2005).
An aneuploid mouse strain carrying human chromosome 21 with Down syndrome
phenotypes. Science 309, 2033–2037.
Ogawa, Y., Nonaka, Y., Goto, T., Ohnishi, E., Hiramatsu, T., Kii, I., Yoshida, M., Ikura, T.,
Onogi, H., Shibuya, H., Hosoya, T., Ito, N., & Hagiwara, M. (2010). Development of
a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat Com-
mun 1, 86.
Olson, L. E., Roper, R. J., Sengstaken, C. L., Peterson, E. A., Aquino, V., Galdzicki, Z., Siarey,
R., Pletnikov, M., Moran, T. H., & Reeves, R. H. (2007). Trisomy for the Down syn-
drome ‘critical region’ is necessary but not sufﬁcient for brain phenotypes of triso-
mic mice. Hum Mol Genet 16, 774–782.
Ortiz-Abalia, J., Sahun, I., Altafaj, X., Andreu, N., Estivill, X., Dierssen, M., & Fillat, C.
(2008). Targeting Dyrk1A with AAVshRNA attenuates motor alterations in
TgDyrk1A, a mouse model of Down syndrome. Am J Hum Genet 83, 479–488.
Philips, A. V., Timchenko, L. T., & Cooper, T. A. (1998). Disruption of splicing regulated
by a CUG-binding protein in myotonic dystrophy. Science 280, 737–741.
Qian, W., Liang, H., Shi, J., Jin, N., Grundke-Iqbal, I., Iqbal, K., Gong, C. X., & Liu, F. (2011).
Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A. Nucleic
Acids Res 39, 6161–6171.
Qiu, Y., Hoareau-Aveilla, C., Oltean, S., Harper, S. J., & Bates, D. O. (2009). The anti-
angiogenic isoforms of VEGF in health and disease. Biochem Soc Trans 37, 1207–1213.
Rajman, I. (2008). PK/PD modelling and simulations: utility in drug development. Drug
Discov Today 13, 341–346.
Roubertoux, P. L., & Carlier, M. (2010). Mouse models of cognitive disabilities in triso-
my 21 (Down syndrome). Am J Med Genet C Semin Med Genet 154C, 400–416.
Roy, A., McDonald, P. R., Sittampalam, S., & Chaguturu, R. (2010). Open access high
throughput drug discovery in the public domain: a Mount Everest in the making.
Curr Pharm Biotechnol 11, 764–778.
Ryoo, S. R., Cho, H. J., Lee, H. W., Jeong, H. K., Radnaabazar, C., Kim, Y. S., Kim, M. J., Son,
M. Y., Seo, H., Chung, S. H., & Song, W. J. (2008). Dual-speciﬁcity tyrosine(Y)-phos-
phorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor
protein: evidence for a functional link between Down syndrome and Alzheimer's
disease. J Neurochem 104, 1333–1344.
Ryoo, S. R., Jeong, H. K., Radnaabazar, C., Yoo, J. J., Cho, H. J., Lee, H. W., Kim, I. S., Cheon,
Y. H., Ahn, Y. S., Chung, S. H., & Song, W. J. (2007). DYRK1A-mediated hyperpho-
sphorylation of Tau. A functional link between Down syndrome and Alzheimer dis-
ease. J Biol Chem 282, 34850–34857.
Sebrie, C., Chabert, C., Ledru, A., Guedj, F., Po, C., Smith, D. J., Rubin, E., Rivals, I., Beloeil,
J. C., Gillet, B., & Delabar, J. M. (2008). Increased dosage of DYRK1A and brain volu-
metric alterations in a YAC model of partial trisomy 21. Anat Rec (Hoboken) 291,
254–262.
Shepard, P. J., & Hertel, K. J. (2009). The SR protein family. Genome Biol 10, 242.
Sherman, S. L., Allen, E. G., Bean, L. H., & Freeman, S. B. (2007). Epidemiology of Down
syndrome. Ment Retard Dev Disabil Res Rev 13, 221–227.
Shi, J., Zhang, T., Zhou, C., Chohan, M. O., Gu, X., Wegiel, J., Zhou, J., Hwang, Y. W., Iqbal,
K., Grundke-Iqbal, I., Gong, C. X., & Liu, F. (2008). Increased dosage of Dyrk1A alters
alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syn-
drome. J Biol Chem 283, 28660–28669.
Shindoh, N., Kudoh, J., Maeda, H., Yamaki, A., Minoshima, S., Shimizu, Y., & Shimizu, N.
(1996). Cloning of a human homolog of the Drosophila minibrain/rat Dyrk gene
from “the Down syndrome critical region” of chromosome 21. Biochem Biophys
Res Commun 225, 92–99.
Smith, D. J., Stevens,M. E., Sudanagunta, S. P., Bronson, R. T., Makhinson,M.,Watabe, A.M.,
O'Dell, T. J., Fung, J., Weier, H. U., Cheng, J. F., & Rubin, E. M. (1997). Functional screen-
ing of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain
in learning defects associated with Down syndrome. Nat Genet 16, 28–36.
Song, W. J., Sternberg, L. R., Kasten-Sportes, C., Keuren, M. L., Chung, S. H., Slack, A. C.,
Miller, D. E., Glover, T. W., Chiang, P. W., Lou, L., & Kurnit, D. M. (1996). Isolation of
human and murine homologues of the Drosophila minibrain gene: human homo-
loguemaps to 21q22.2 in theDown syndrome “critical region”.Genomics 38, 331–339.
305Y. Ogawa, M. Hagiwara / Pharmacology & Therapeutics 134 (2012) 298–305Tejedor, F. J., & Hammerle, B. (2011). MNB/DYRK1A as a multiple regulator of neuronal
development. FEBS J 278, 223–235.
Thomas, C. J., Auld, D. S., Huang, R., Huang, W., Jadhav, A., Johnson, R. L., Leister, W.,
Maloney, D. J., Marugan, J. J., Michael, S., Simeonov, A., Southall, N., Xia, M.,
Zheng, W., Inglese, J., & Austin, C. P. (2009). The pilot phase of the NIH Chemical
Genomics Center. Curr Top Med Chem 9, 1181–1193.
Toiber, D., Azkona, G., Ben-Ari, S., Toran, N., Soreq, H., & Dierssen, M. (2010). Engineering
DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberra-
tions. Neurobiol Dis 40, 348–359.
Vilardell, M., Rasche, A., Thormann, A., Maschke-Dutz, E., Perez-Jurado, L. A., Lehrach,
H., & Herwig, R. (2011). Meta-analysis of heterogeneous Down Syndrome data
reveals consistent genome-wide dosage effects related to neurological processes.
BMC Genomics 12, 229.
Wagner, K. R., Hamed, S., Hadley, D. W., Gropman, A. L., Burstein, A. H., Escolar, D. M.,
Hoffman, E. P., & Fischbeck, K. H. (2001). Gentamicin treatment of Duchenne and
Becker muscular dystrophy due to nonsense mutations. Ann Neurol 49, 706–711.
Wang, G. S., Kuyumcu-Martinez, M. N., Sarma, S., Mathur, N., Wehrens, X. H. T., &
Cooper, T. A. (2009). PKC inhibition ameliorates the cardiac phenotype in a
mouse model of myotonic dystrophy type 1. J Clin Invest 119, 3797–3806.
Warf, M. B., Nakamori, M., Matthys, C. M., Thornton, C. A., & Berglund, J. A. (2009). Pent-
amidine reverses the splicing defects associated with myotonic dystrophy. Proc
Natl Acad Sci U S A 106, 18551–18556.
Wegiel, J., Dowjat, K., Kaczmarski, W., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur
Kolecka, B., Wegiel, J., Silverman, W. P., Reisberg, B., Deleon, M., Wisniewski, T.,
Gong, C. X., Liu, F., Adayev, T., Chen-Hwang, M. C., & Hwang, Y. W. (2008). The
role of overexpressed DYRK1A protein in the early onset of neuroﬁbrillary
degeneration in Down syndrome. Acta Neuropathol 116, 391–407.Wegiel, J., Gong, C. X., & Hwang, Y. W. (2011). The role of DYRK1A in neurodegenerative
diseases. FEBS J 278, 236–245.
Welch, E. M., Barton, E. R., Zhuo, J., Tomizawa, Y., Friesen, W. J., Triﬁllis, P., Paushkin, S.,
Patel, M., Trotta, C. R., Hwang, S., Wilde, R. G., Karp, G., Takasugi, J., Chen, G., Jones,
S., Ren, H., Moon, Y. C., Corson, D., Turpoff, A. A., Campbell, J. A., Conn, M. M., Khan,
A., Almstead, N. G., Hedrick, J., Mollin, A., Risher, N., Weetall, M., Yeh, S., Branstrom,
A. A., Colacino, J. M., Babiak, J., Ju, W. D., Hirawat, S., Northcutt, V. J., Miller, L. L.,
Spatrick, P., He, F., Kawana, M., Feng, H., Jacobson, A., Peltz, S. W., & Sweeney,
H. L. (2007). PTC124 targets genetic disorders caused by nonsensemutations.Nature
447, 87–91.
Wiseman, F. K., Alford, K. A., Tybulewicz, V. L., & Fisher, E. M. (2009). Down syndrome—
recent progress and future prospects. Hum Mol Genet 18, R75–R83.
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985). Occurrence of neuropatho-
logical changes and dementia of Alzheimer's disease in Down's syndrome. Ann
Neurol 17, 278–282.
Woods, Y. L., Cohen, P., Becker, W., Jakes, R., Goedert, M., Wang, X., & Proud, C. G.
(2001). The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bep-
silon at Ser539 and the microtubule-associated protein tau at Thr212: potential role
for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J 355, 609–615.
Yomoda, J., Muraki, M., Kataoka, N., Hosoya, T., Suzuki, M., Hagiwara, M., & Kimura, H.
(2008). Combination of Clk family kinase and SRp75 modulates alternative splicing
of Adenovirus E1A. Genes Cells 13, 233–244.
Yu, T., Li, Z., Jia, Z., Clapcote, S. J., Liu, C., Li, S., Asrar, S., Pao, A., Chen, R., Fan, N., Carattini-
Rivera, S., Bechard, A. R., Spring, S., Henkelman, R. M., Stoica, G., Matsui, S., Nowak,
N. J., Roder, J. C., Chen, C., Bradley, A., & Yu, Y. E. (2010). A mouse model of Down
syndrome trisomic for all human chromosome 21 syntenic regions. Hum Mol
Genet 19, 2780–2791.
